Tagged: cost cutting

Labeling: Your Map to Market

In response to the spectrum of interaction that I have experienced with this blog’s readers, I am excited to announce that guest writers from the Health Decisions staff will begin contributing to Trials without Tribulations. I will have one guest blogger each month. Health Decisions staff members with deep experience in clinical research will share… Read more »

Surviving the Big Squeeze in Biopharma Development

The biopharma industry finds itself in a squeeze that rivals the drama of the garbage-compactor scene in Star Wars. On one side, operational inefficiency keeps closing in. Outlook 2013 from the Tufts Center for the Study of Drug Development reminds us that new business models haven’t solved the industry’s efficiency problems. Another recent Tufts CSDD… Read more »

The Rhetoric of “Risk Sharing”

Derek Lowe’s observation about AstraZeneca’s bracing for change also applies to the pharma industry as a whole: “…things can’t go on the way that they have been.” AstraZeneca is not alone in failing to get enough new drugs approved to sustain their business model, but they’ve made themselves the poster child for that dilemma. Somehow… Read more »